Abstract
Hepatic organoid technology holds great promise for the development of future Regenerative Medicine strategies to treat patients with severe liver disease. Recently, some studies have demonstrated robust protocols for isogenic organoid generation using induced Pluripotent Stem cells (iPS). However, using patient's specific iPS-derived cells poses a major challenge for a translational pers…